Annual EBITDA
-$596.42 M
-$524.55 M-729.89%
December 31, 2023
Summary
- As of February 7, 2025, SMMT annual EBITDA is -$596.42 million, with the most recent change of -$524.55 million (-729.89%) on December 31, 2023.
- During the last 3 years, SMMT annual EBITDA has fallen by -$545.76 million (-1077.48%).
- SMMT annual EBITDA is now -5217.26% below its all-time high of $11.65 million, reached on January 31, 2019.
Performance
SMMT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$53.78 M
+$3.48 M+6.08%
September 30, 2024
Summary
- As of February 7, 2025, SMMT quarterly EBITDA is -$53.78 million, with the most recent change of +$3.48 million (+6.08%) on September 30, 2024.
- Over the past year, SMMT quarterly EBITDA has increased by +$3.48 million (+6.08%).
- SMMT quarterly EBITDA is now -248.20% below its all-time high of $36.29 million, reached on July 31, 2018.
Performance
SMMT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$183.16 M
-$35.27 M-23.85%
September 30, 2024
Summary
- As of February 7, 2025, SMMT TTM EBITDA is -$183.16 million, with the most recent change of -$35.27 million (-23.85%) on September 30, 2024.
- Over the past year, SMMT TTM EBITDA has dropped by -$35.27 million (-23.85%).
- SMMT TTM EBITDA is now -1327.33% below its all-time high of $14.92 million, reached on April 1, 2019.
Performance
SMMT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SMMT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -729.9% | +6.1% | -23.9% |
| 3 y3 years | -1077.5% | -241.9% | -154.8% |
| 5 y5 years | -5217.3% | -470.9% | -592.9% |
SMMT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -729.9% | at low | -342.4% | +89.9% | -154.8% | +69.3% |
| 5 y | 5-year | -2095.8% | at low | -504.9% | +89.9% | -621.0% | +69.3% |
| alltime | all time | -5217.3% | at low | -248.2% | +89.9% | -1327.3% | +69.3% |
Summit Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$53.78 M(-6.1%) | -$183.16 M(+23.8%) |
| Jun 2024 | - | -$57.26 M(+42.0%) | -$147.89 M(+43.9%) |
| Mar 2024 | - | -$40.33 M(+26.9%) | -$102.78 M(-82.8%) |
| Dec 2023 | -$596.42 M(+729.9%) | -$31.79 M(+71.7%) | -$596.42 M(+2.8%) |
| Sep 2023 | - | -$18.51 M(+52.3%) | -$580.36 M(-0.3%) |
| Jun 2023 | - | -$12.16 M(-97.7%) | -$581.83 M(-0.6%) |
| Mar 2023 | - | -$533.96 M(+3294.7%) | -$585.20 M(+714.3%) |
| Dec 2022 | -$71.87 M(-16.3%) | -$15.73 M(-21.3%) | -$71.87 M(-13.0%) |
| Sep 2022 | - | -$19.98 M(+28.7%) | -$82.57 M(+1.2%) |
| Jun 2022 | - | -$15.53 M(-24.7%) | -$81.55 M(-8.9%) |
| Mar 2022 | - | -$20.63 M(-21.9%) | -$89.56 M(+4.9%) |
| Dec 2021 | -$85.91 M(+69.6%) | -$26.43 M(+39.3%) | -$85.37 M(+21.7%) |
| Sep 2021 | - | -$18.97 M(-19.4%) | -$70.16 M(+5.0%) |
| Jun 2021 | - | -$23.54 M(+43.2%) | -$66.81 M(+14.8%) |
| Mar 2021 | - | -$16.44 M(+46.5%) | -$58.20 M(+14.9%) |
| Dec 2020 | -$50.65 M(+86.5%) | - | - |
| Dec 2020 | - | -$11.22 M(-28.2%) | -$50.65 M(+28.5%) |
| Sep 2020 | - | -$15.62 M(+4.7%) | -$39.43 M(+18.7%) |
| Jun 2020 | - | -$14.92 M(+67.9%) | -$33.23 M(+30.8%) |
| Mar 2020 | - | -$8.89 M(-5.6%) | -$25.40 M(-3.9%) |
| Dec 2019 | -$27.16 M(-333.1%) | - | - |
| Oct 2019 | - | -$9.42 M(+32.8%) | -$26.43 M(-7.1%) |
| Jul 2019 | - | -$7.09 M(+23.1%) | -$28.46 M(-290.7%) |
| Apr 2019 | - | -$5.76 M(+38.6%) | $14.92 M(+23.1%) |
| Jan 2019 | $11.65 M(-136.2%) | - | - |
| Jan 2019 | - | -$4.16 M(-63.7%) | $12.12 M(>+9900.0%) |
| Oct 2018 | - | -$11.45 M(-131.5%) | $69.30 K(-99.2%) |
| Jul 2018 | - | $36.29 M(-523.7%) | $8.77 M(-126.4%) |
| Apr 2018 | - | -$8.56 M(-47.2%) | -$33.18 M(+3.7%) |
| Jan 2018 | -$32.19 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2018 | - | -$16.21 M(+491.0%) | -$32.00 M(+33.7%) |
| Oct 2017 | - | -$2.74 M(-51.6%) | -$23.93 M(-13.4%) |
| Jul 2017 | - | -$5.66 M(-23.4%) | -$27.62 M(-12.5%) |
| Apr 2017 | - | -$7.39 M(-9.2%) | -$31.58 M(-4.9%) |
| Jan 2017 | -$30.98 M(+7.2%) | - | - |
| Jan 2017 | - | -$8.14 M(+26.4%) | -$33.20 M(+3.2%) |
| Oct 2016 | - | -$6.43 M(-33.1%) | -$32.18 M(-5.8%) |
| Jul 2016 | - | -$9.62 M(+6.8%) | -$34.17 M(+6.7%) |
| Apr 2016 | - | -$9.01 M(+26.5%) | -$32.02 M(+11.0%) |
| Jan 2016 | -$28.91 M(+57.9%) | - | - |
| Jan 2016 | - | -$7.12 M(-15.4%) | -$28.86 M(+13.6%) |
| Oct 2015 | - | -$8.42 M(+12.7%) | -$25.40 M(+18.6%) |
| Jul 2015 | - | -$7.47 M(+27.8%) | -$21.41 M(+7.2%) |
| Apr 2015 | - | -$5.84 M(+59.2%) | -$19.98 M(+5.9%) |
| Jan 2015 | -$18.30 M(+66.1%) | - | - |
| Jan 2015 | - | -$3.67 M(-17.1%) | -$18.86 M(-2.5%) |
| Oct 2014 | - | -$4.43 M(-26.6%) | -$19.35 M(+6.5%) |
| Jul 2014 | - | -$6.04 M(+27.6%) | -$18.17 M(+49.7%) |
| Apr 2014 | - | -$4.73 M(+13.8%) | -$12.14 M(+63.9%) |
| Jan 2014 | -$11.02 M(+55.8%) | - | - |
| Jan 2014 | - | -$4.16 M(+28.1%) | -$7.40 M(+128.1%) |
| Oct 2013 | - | -$3.25 M | -$3.25 M |
| Jan 2013 | -$7.07 M(+60.5%) | - | - |
| Jan 2012 | -$4.41 M(-49.0%) | - | - |
| Jan 2011 | -$8.65 M(+59.9%) | - | - |
| Jan 2010 | -$5.41 M(-66.3%) | - | - |
| Jan 2009 | -$16.03 M(-13.8%) | - | - |
| Jan 2008 | -$18.58 M(+203.0%) | - | - |
| Jan 2007 | -$6.13 M(+106.4%) | - | - |
| Jan 2006 | -$2.97 M(+463.8%) | - | - |
| Jan 2005 | -$527.20 K | - | - |
FAQ
- What is Summit Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Summit Therapeutics?
- What is Summit Therapeutics annual EBITDA year-on-year change?
- What is Summit Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Summit Therapeutics?
- What is Summit Therapeutics quarterly EBITDA year-on-year change?
- What is Summit Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Summit Therapeutics?
- What is Summit Therapeutics TTM EBITDA year-on-year change?
What is Summit Therapeutics annual EBITDA?
The current annual EBITDA of SMMT is -$596.42 M
What is the all time high annual EBITDA for Summit Therapeutics?
Summit Therapeutics all-time high annual EBITDA is $11.65 M
What is Summit Therapeutics annual EBITDA year-on-year change?
Over the past year, SMMT annual EBITDA has changed by -$524.55 M (-729.89%)
What is Summit Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SMMT is -$53.78 M
What is the all time high quarterly EBITDA for Summit Therapeutics?
Summit Therapeutics all-time high quarterly EBITDA is $36.29 M
What is Summit Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SMMT quarterly EBITDA has changed by +$3.48 M (+6.08%)
What is Summit Therapeutics TTM EBITDA?
The current TTM EBITDA of SMMT is -$183.16 M
What is the all time high TTM EBITDA for Summit Therapeutics?
Summit Therapeutics all-time high TTM EBITDA is $14.92 M
What is Summit Therapeutics TTM EBITDA year-on-year change?
Over the past year, SMMT TTM EBITDA has changed by -$35.27 M (-23.85%)